CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Meletios is developing a novel antiviral treatment that targets cellular mechanisms exploited by viruses. This oral agent aims to provide broad-spectrum efficacy against various viral infections, with initial focus on COVID-19, while also modulating immune responses.
Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections.
Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses.
By acting on cell membranes fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses.
This approach could be effective against broad virus families, conferring our molecule with an adva…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
